1
New nonfatal MI and cardiac death were the study end points.
2
The HR for nonfatal MI and for acute CHD death was also nonsignificant.
3
Main outcome measure: Risk of the combined outcome of first nonfatal MI or stroke.
4
Significant associations with nonfatal MI were not evident.
5
Results: Overall, a total of 5,898 cases of nonfatal MI cases were recorded.
6
Risk reductions in cardiovascular death or nonfatal MI were similar across predetermined subgroups and the component CHARM trials.
7
Conclusion: In patients with heart failure, candesartan significantly reduces the risk of the composite outcome of cardiovascular death or nonfatal MI.
8
Medicare claims were used to identify outcomes of cardiovascular mortality, nonfatal myocardial infarction (MI), fatal or nonfatal MI, stroke, and peripheral arterial disease.
9
By the end of follow-up, cardiac death was observed in 22.4% and nonfatal MI in 16.1% of the patients.